Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Rilonacept Articles

US FDA rejects Regeneron's Arcalyst sBLA for gout flare prevention

1 August 2012

USA: FDA panel votes against Regeneron gout drug; Court upholds Abilify patent

9 May 2012

Second positive trial for Regeneron's gout drug Arcalyst

1 March 2011

New study highlights changes in the management of gout and hyperuricemia among US rheumatologists and PCPs

2 March 2010

Regeneron initiates Ph III Arcalyst study

27 March 2009

Arcalyst reduces gout flares 81% in Ph II trial

15 September 2008

Thomson releases Pharma Matters reports for 1st qtr

1 September 2008

US FDA set for even fewer approvals in 2008

1 September 2008

Regeneron's Arcalyst available in USA

31 March 2008

FDA clears Regeneron's Arcalyst

10 March 2008

Regeneron's CAPS drug cleared by FDA

3 March 2008

Showing 1-11 of 11 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Elan makes "transformational" acquisitions and a divestment
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Elan makes "transformational" acquisitions and a divestment

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS